 CHENGDU, China, and SAN DIEGO, June 01, 2022 GLOBE NEWSWIRE -- Sichuan Kelun-Biotech Biopharmaceutical Co, Ltd. Kelun-Biotech and Levena Biopharma Levena, a subsidiary of Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento, today announced the planned presentation of A166 data Abstract 1037 and Poster 415 in patients with HER2-expressing locally advanced or metastatic solid tumors at the 2022 Annual Meeting of ASCO, the American Society of Clinical Oncology, to be held on June 3-7 in Chicago, IL. A166 is a HER2 antibody-drug conjugate ADC developed by Kelun-Biotech in a partnership with Levena Biopharma, which provided the patent-protected technologies for the generation and production of A166 in relation to 1 Duostatin-5, a proprietary tubulin inhibitor, 2 K-Lock, a site-specific conjugation technology, and 3 an enzymatically cleavable linker. 